5 can&#x27;t miss studies

Food Insecurity and the Dangers of Infant Formula Dilution

Music therapist Jenna Marcovitz discusses the role of pediatricians in making timely referrals to music therapy to support whole-child health.

January 30th 2023

Phase 3 data show effectiveness of somapacitan in children with growth disorders

Demystifying Infant Formula

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.

October 11th 2022

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients

Morgan Ebert, Managing Editor

FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years

Safety, phosphate level gains, and immunogenicity data offer encouraging signals in the pivotal trial.

FDA accepts NDA for berotralstat in HEA patients aged 2 to 11 years | Image credit: Contemporary Pediatrics

Connecting families to music therapy, with Jenna Marcovitz, MA

The federal agency provided BioCryst Pharmaceuticals a target action date of September 12, 2025 for potential approval of berotralstat (ORLADEYO).

Related Content

Jenna Marcovitz, MA, MT-BC, CCLS, RMT

Food Insecurity and the Dangers of Infant Formula Dilution

Music therapist Jenna Marcovitz discusses the role of pediatricians in making timely referrals to music therapy to support whole-child health.

January 30th 2023

Phase 3 data show effectiveness of somapacitan in children with growth disorders

Demystifying Infant Formula

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.

October 11th 2022

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients

Morgan Ebert, Managing Editor

FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years

Safety, phosphate level gains, and immunogenicity data offer encouraging signals in the pivotal trial.